Sansure Immunological Technology Platform adopts advanced nanoparticle technology, protein labelling and modification technology, using high quality coloured latex and colloidal gold as tracers, and has developed a series of easy-to-use, highly sensitive and rapid detection products, covering SARS-CoV-2 antigen, SARS-CoV-2/InFluA/InFluB antigen, SARS-CoV-2 neutralizing antibody and other SARS-CoV-2 immunological reagents, to meet the needs of different scenarios such as home self-test, POCT and laboratory testing.
On June 20, Jo Hawley, the British Consul General in Guangzhou, and Mr. Mike McCourt, Healthcare Director in China for the British Department of International Trade China, visited Sansure Biothech. They were accompanied by the management from Changsha High-Tech Development Zone, along with Dr. Lizhong Dai, the Chairman of Sansure. During the visit, they had an in-depth discussion on further […]
On June 7, the new generation of iPonatic full-automatic nucleic acid testing and analysis system of Sansure Biotech was certified by IVDR CE, which will better serve the construction of public health prevention and control system globally. CE certification is mandatory for product access to the EU market. From May 26, 2022, the EU comprehensively implemented in vitro diagnosis medical […]
On June 8, Singlera Genomics (Shanghai) Ltd. (hereinafter referred to as “Singlera Genomics”) announced that it had completed a 300 million yuan B+ round of financing. This round of financing is led by Forestone Capital, followed by funds from Yinhe Yuanhui, Guojing Capital, Junci Investment, Qiandao Investment, Best, Brilliance Investment. As a strategic investor, Sansure Biotech followed the investment, and […]
Sansure Biotech Inc. released its 2021 annual report and 2022 Q1 report. Under the severe challenge of the COVID-19 pandemic, the company independently developed various products and achieved brilliant achievements. This report summarizes Sansure’s 2021 achievements, including revenue, R&D priorities, and significant future direction. Sansure maintains a leading position in the medical industry, with stable revenue and strong resilience. In […]
On May 25, the Monkeypox virus Nucleic Acid Diagnostic Kit developed by Sansure Biotech successfully obtained the CE certification, which means that the kit can be distributed in EU countries and countries that recognize the CE certification. Currently, unusual cases of monkeypox have been reported in several countries, including the United Kingdom, Spain, and Portugal, posing a challenge to human […]